# A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)

> **NCT07331272** · PHASE1 · RECRUITING · sponsor: **Nanjing Legend Biotech Co.** · enrollment: 38 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)
- Idiopathic Inflammatory Myopathies(IIM)

## Interventions

- **BIOLOGICAL:** LUCAR-G79D T cells

## Key facts

- **NCT ID:** NCT07331272
- **Lead sponsor:** Nanjing Legend Biotech Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2028-01-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07331272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07331272, "A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07331272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*